| Source: Xvivo Perfusion AB
The Annual General Meeting of XVIVO Perfusion AB (publ) will take place on
Tuesday April 29, 2014, at 5 p.m. in the company's premises at Mässans gata 10
in Gothenburg. Notice of attendance at the Annual General Meeting shall be given
no later than Wednesday, April 23, 2014.
Shareholders wishing to participate at the Annual General Meeting shall notify
the company by mail to XVIVO Perfusion AB (publ), Box 53015, SE-400 14
Gothenburg, Sweden, Att: Catrin Olsson, by phone +46 31-788 21 53, by fax +46 31
-788 21 69 or by e-mail Name/business name,
personal identification number/ company registration number (or the equivalent),
address, telephone number, number of shares, details of any advisors and where
appropriate details of a representative or proxy must be stated in the
notification. A proxy form in Swedish for shareholders wishing to be represented
by proxy will be found on

Shareholders that have their shares registered in the name of a nominee must
temporarily record their shares in the share register kept by Euroclear Sweden
AB in their own names to be able to attend the General Meeting. Such
registration must be carried out no later than Wednesday, April 23, 2014.

Attachment: Full notice (in Swedish)

March 28, 2014
XVIVO Perfusion AB (publ)
The Board
Queries should be addressed to:

Fredrik Mattsson, Chairman of the Board, phone +46 8-614 00 20
Christoffer Rosenblad, CFO, phone +46 31-788 21 59

Xvivo Perfusion is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
28, 2014 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.

XVIVO Perfusion AB is a medical technology company which develops solutions and
systems for assessing and preserving organs outside the body and for selecting
usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the
USA. The XVIVO share is listed on NASDAQ OMX First North and has the ticker
symbol XVIVO. More information can be found on the website The Certified Adviser is Redeye,

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity
number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website: